Mylan launches generic version of Abbott’s Trilipix Capsule in US
Known as Fenofibric Acid Delayed-release Capsules, 45mg and 135mg is indicated for patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Meeting the standards of child-resistant packaging, the new Kush containers are constructed with medical grade plastic, utilizing FDA approved material, and are BPA-free. Kush Bottles chief operating officer
The collaboration is focused on the development of a new generation of steroids and steroids related pharmaceuticals for rapid subcutaneous absorption. PharmaNova’s NovaSperse nanoparticle technology will be leveraged
The Swiss agency for therapeutic products, Swissmedic, cleared tofacitinib 5mg and 10mg twice-daily (BID) as monotherapy or combination therapy along with a disease modifying non-biologic antirheumatic agent (DMARD)